MA54384A - Inhibiteurs de morpholinyle, de pipérazinyle, d'oxazépanyle et de diazépanyle o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase - Google Patents

Inhibiteurs de morpholinyle, de pipérazinyle, d'oxazépanyle et de diazépanyle o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase

Info

Publication number
MA54384A
MA54384A MA054384A MA54384A MA54384A MA 54384 A MA54384 A MA 54384A MA 054384 A MA054384 A MA 054384A MA 54384 A MA54384 A MA 54384A MA 54384 A MA54384 A MA 54384A
Authority
MA
Morocco
Prior art keywords
glucopyranosidase
oxazepanyl
desoxy
diazepanyl
acetamido
Prior art date
Application number
MA054384A
Other languages
English (en)
Inventor
Nathan Genung
Ryan Gianatassio
Kevin M Guckian
Edward Yin Shiang Lin
Jeffrey Vessels
Zhili Xin
Lei Zhang
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA54384A publication Critical patent/MA54384A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA054384A 2018-12-05 2019-12-04 Inhibiteurs de morpholinyle, de pipérazinyle, d'oxazépanyle et de diazépanyle o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase MA54384A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862775558P 2018-12-05 2018-12-05

Publications (1)

Publication Number Publication Date
MA54384A true MA54384A (fr) 2021-10-13

Family

ID=69006035

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054384A MA54384A (fr) 2018-12-05 2019-12-04 Inhibiteurs de morpholinyle, de pipérazinyle, d'oxazépanyle et de diazépanyle o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase

Country Status (9)

Country Link
US (1) US12319679B2 (fr)
EP (2) EP3891146B1 (fr)
JP (1) JP7607562B2 (fr)
AR (1) AR117252A1 (fr)
ES (1) ES2968733T3 (fr)
MA (1) MA54384A (fr)
TW (1) TW202039482A (fr)
UY (1) UY38498A (fr)
WO (1) WO2020117961A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102533471B1 (ko) * 2020-11-23 2023-05-19 (주) 메디프론디비티 O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도
WO2025247394A1 (fr) * 2024-05-31 2025-12-04 纽欧申医药(上海)有限公司 Composé hétérocyclique contenant de l'azote, composition pharmaceutique de celui-ci et utilisation associée

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP2780014A4 (fr) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (fr) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
MA38341B1 (fr) 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
PT2970272T (pt) * 2013-03-14 2019-06-05 Merck Patent Gmbh Inibidores de glicosidase
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
US20190359609A1 (en) 2016-12-16 2019-11-28 Janssen Pharmaceutica Nv Bicyclic oga inhibitor compounds
EP3555087A1 (fr) * 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Composés inhibiteurs d'oga monocyclique
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5－甲基－1,2,4－二唑－3－基化合物
WO2018154133A1 (fr) * 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga

Also Published As

Publication number Publication date
US20220017506A1 (en) 2022-01-20
AR117252A1 (es) 2021-07-21
ES2968733T3 (es) 2024-05-13
EP4327814A2 (fr) 2024-02-28
JP2022510430A (ja) 2022-01-26
WO2020117961A1 (fr) 2020-06-11
JP7607562B2 (ja) 2024-12-27
US12319679B2 (en) 2025-06-03
EP4327814A3 (fr) 2024-04-24
EP3891146B1 (fr) 2023-09-27
UY38498A (es) 2020-07-31
TW202039482A (zh) 2020-11-01
EP3891146A1 (fr) 2021-10-13

Similar Documents

Publication Publication Date Title
IL285178A (en) Compounds and uses thereof
IL282487A (en) Tyk2 inhibitors and uses thereof
CL2020002791A1 (es) Dispositivos y métodos para engastar implantes protésicos.
ZA202006904B (en) Anti-il-4r antibody and use thereof
EP3992209A4 (fr) Anticorps cldn18.2 et son utilisation
EP3740224A4 (fr) Anticorps anti-lilrb et leurs utilisations
IL282090A (en) Tyk2 inhibitors and uses thereof
LT3788042T (lt) Bcl-2 inhibitoriai
SG11202100746WA (en) Anti-tigit antibody and use thereof
HUE052067T2 (hu) Mutáns IDH1 és mutáns IDH2 inhibitor 7-feniletilamino-4H-pirimido[4,5-d][1,3]oxazin-2-on vegyületek
PL3618928T3 (pl) Przeciwciała antysortylinowe i sposoby ich stosowania
EP3904382A4 (fr) Anticorps anti-il-23p19 et ses utilisations
EP4071172A4 (fr) Anticorps anti-lilrb1 et ses utilisations
EP3826721C0 (fr) Composés de naphtyridine et leurs utilisations
IL280631A (en) Novel crispr-associated protein and use thereof
EP4008141C0 (fr) Équipement utilisateur et noeud de planification
EP4025609A4 (fr) Anticorps anti-steap1 et leurs utilisations
EP3868408A4 (fr) Antipsychotique et utilisation associée
IL283875A (en) Anti-il-27 antibodies and uses thereof
HUE063120T2 (hu) LRRC33-inhibitorok és alkalmazásuk
IL284514A (en) Halo-allylamine compounds and use thereof
EP3790527A4 (fr) Nébuliseurs, cartouches de nébuliseur et leurs utilisations
EP3856755A4 (fr) Dérivés de terpinoïdes et leurs utilisations
EP3803395A4 (fr) Cartouche microfluidique, kit et dosage
EP4456606C0 (fr) Équipment utilisateur et appareil